Characteristics of patients included in the study
| . | FcγRIIa . | FcγRIIIa . | ||||||
|---|---|---|---|---|---|---|---|---|
| R/R (n = 64) . | R/H (n = 235) . | H/H (n = 213) . | P . | V/V (n = 145) . | V/F (n = 271) . | F/F (n = 96) . | P . | |
| Male | 36 (56%) | 131 (56%) | 105 (49%) | .340 | 81 (56%) | 139 (51%) | 52 (54%) | .656 |
| Median age y (range) | 67 (61-80) | 68 (61-80) | 68 (61-80) | .252 | 68 (61-80) | 69 (61-80) | 67 (61-79) | .143 |
| LDH > UNV | 28 (44%) | 125 (53%) | 97 (46%) | .184 | 66 (46%) | 137 (51%) | 47 (49%) | .623 |
| ECOG PS > 1 | 9 (14%) | 32 (14%) | 26 (12%) | .870 | 16 (11%) | 37 (14%) | 14 (15%) | .669 |
| Stage III/ IV | 29 (45%) | 128 (54%) | 101 (47%) | .223 | 73 (50%) | 137 (51%) | 48 (50%) | 1.000 |
| Extranodal sites > 1 | 8 (13%) | 44 (19%) | 32 (15%) | .405 | 25 (17%) | 47 (17%) | 12 (13%) | .511 |
| IPI | 22 (34%) | 63 (27%) | 79 (37%) | .210 | 48 (33%) | 29 (30%) | .319 | |
| 1 | 21 (33%) | 65 (28%) | 49 (23%) | 44 (30%) | 87 (32%) | 26 (27%) | ||
| 2 | 12 (19%) | 68 (29%) | 54 (25%) | 28 (19%) | 65 (24%) | 30 (31%) | ||
| 3 | 9 (14%) | 39 (17%) | 31 (15%) | 25 (17%) | 76 (28%) | 11 (11%) | ||
| 4, 5 | 43 (16%) | |||||||
| Bulky disease | 23 (36%) | 103 (44%) | 80 (38%) | .311 | 52 (36%) | 111 (41%) | 43 (45%) | .368 |
| B symptoms | 16 (25%) | 86 (37%) | 70 (33%) | .214 | 38 (26%) | 94 (35%) | 40 (42%) | .037 |
| BM involvement | 4 (6%) | 10 (4%) | 14 (7%) | .518 | 7 (5%) | 16 (6%) | 5 (5%) | .965 |
| . | FcγRIIa . | FcγRIIIa . | ||||||
|---|---|---|---|---|---|---|---|---|
| R/R (n = 64) . | R/H (n = 235) . | H/H (n = 213) . | P . | V/V (n = 145) . | V/F (n = 271) . | F/F (n = 96) . | P . | |
| Male | 36 (56%) | 131 (56%) | 105 (49%) | .340 | 81 (56%) | 139 (51%) | 52 (54%) | .656 |
| Median age y (range) | 67 (61-80) | 68 (61-80) | 68 (61-80) | .252 | 68 (61-80) | 69 (61-80) | 67 (61-79) | .143 |
| LDH > UNV | 28 (44%) | 125 (53%) | 97 (46%) | .184 | 66 (46%) | 137 (51%) | 47 (49%) | .623 |
| ECOG PS > 1 | 9 (14%) | 32 (14%) | 26 (12%) | .870 | 16 (11%) | 37 (14%) | 14 (15%) | .669 |
| Stage III/ IV | 29 (45%) | 128 (54%) | 101 (47%) | .223 | 73 (50%) | 137 (51%) | 48 (50%) | 1.000 |
| Extranodal sites > 1 | 8 (13%) | 44 (19%) | 32 (15%) | .405 | 25 (17%) | 47 (17%) | 12 (13%) | .511 |
| IPI | 22 (34%) | 63 (27%) | 79 (37%) | .210 | 48 (33%) | 29 (30%) | .319 | |
| 1 | 21 (33%) | 65 (28%) | 49 (23%) | 44 (30%) | 87 (32%) | 26 (27%) | ||
| 2 | 12 (19%) | 68 (29%) | 54 (25%) | 28 (19%) | 65 (24%) | 30 (31%) | ||
| 3 | 9 (14%) | 39 (17%) | 31 (15%) | 25 (17%) | 76 (28%) | 11 (11%) | ||
| 4, 5 | 43 (16%) | |||||||
| Bulky disease | 23 (36%) | 103 (44%) | 80 (38%) | .311 | 52 (36%) | 111 (41%) | 43 (45%) | .368 |
| B symptoms | 16 (25%) | 86 (37%) | 70 (33%) | .214 | 38 (26%) | 94 (35%) | 40 (42%) | .037 |
| BM involvement | 4 (6%) | 10 (4%) | 14 (7%) | .518 | 7 (5%) | 16 (6%) | 5 (5%) | .965 |